Who Optimizes SG&A Costs Better? Takeda Pharmaceutical Company Limited or HUTCHMED (China) Limited

SG&A Cost Strategies: Takeda vs. HUTCHMED

__timestampHUTCHMED (China) LimitedTakeda Pharmaceutical Company Limited
Wednesday, January 1, 201426684000612613000000
Thursday, January 1, 201529829000650773000000
Friday, January 1, 201639578000619061000000
Sunday, January 1, 201743277000628106000000
Monday, January 1, 201848645000717599000000
Tuesday, January 1, 201952934000964737000000
Wednesday, January 1, 202061349000875663000000
Friday, January 1, 2021127125000886361000000
Saturday, January 1, 2022136106000997309000000
Sunday, January 1, 20231331759991053819000000
Monday, January 1, 20241053819000000
Loading chart...

Data in motion

Optimizing SG&A Costs: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Takeda Pharmaceutical Company Limited and HUTCHMED (China) Limited, two industry leaders, showcase contrasting strategies in this domain. From 2014 to 2023, Takeda's SG&A expenses have consistently been over 10,000 times higher than HUTCHMED's, reflecting its expansive global operations. However, HUTCHMED has shown a remarkable growth trajectory, with its SG&A costs increasing by approximately 400% over the same period, indicating aggressive expansion and investment in its operations.

Takeda's expenses peaked in 2023, reaching over 1 trillion, while HUTCHMED's expenses saw a significant rise in 2021, doubling from the previous year. This data highlights the different scales and strategies of these companies, with Takeda focusing on maintaining its vast operations and HUTCHMED investing heavily in growth. Missing data for 2024 suggests ongoing developments in this dynamic industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025